UNSPSC 51313710: Zolamine hydrochloride

This classification denotes a histamine-1 receptor antagonist with the molecular formula C15H21N3OS.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier C2B9CF1640, chemically known as 1,2-ethanediamine, n-((4-methoxyphenyl)methyl)-n,n-dimethyl-n-2-thiazolyl-, monohydrochloride but more generally known as zolamine hydrochloride, which bears US NIH Compound Identifier 14386. Most nations, for tariff and trade purposes, schedule zolamine hydrochloride under HS 29341000 and SITC 51579.

As of Q4 2014, ZOLAMINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Zolamine hydrochloride bears US NLM identifiers UMLS ID C2825476 and NCI Concept Code C81149. SMILES: CN(C)CCN(CC1CCC(CC1)OC)C2NCCS2.CL.

UNSPSC 51313710 Zolamine hydrochloride (Commodity) covers pharmaceutical active ingredients and finished drug products procured by state and local health agencies, though recent activity under this code shows limited direct solicitation for zolamine itself; state and local governments are instead purchasing naloxone, generic multi-source pharmaceuticals, and OTC products through competitive bidding, cooperative purchasing agreements, and market-intelligence-gathering RFIs designed to establish supply channels and manage pharmacy benefit programs. Issuing bodies include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance serving multiple states including Oregon), with these entities procuring for community health initiatives, employee health plans, and pharmacy benefit programs through both direct purchase agreements and wholesaler-mediated distribution networks.

Recent activity spans Florida, Texas, and Minnesota-led multistate procurement. Seminole County, Florida released IFB 60459723LAS on June 30, 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2023 and quarterly deliveries to the Seminole County Community Health Building; the contract includes a two-year initial term with one-year renewal option and requires fixed-fee pricing with shipping included. The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026 to gather vendor capabilities for direct-to-manufacturer prescription programs outside traditional PBM and GPO arrangements. The Minnesota Multistate Cooperative Purchasing Alliance posted RFP S1070000015802 on January 20, 2026 for generic multi-source pharmaceuticals and OTC products, with a response deadline of March 26, 2026 and awards effective July 1, 2026; the RFP requires cGMP and DSCSA compliance, EDI capability, and pricing submission through authorized wholesalers (AmerisourceBergen, Cardinal Health, Morris & Dickson), with evaluation weighted 75 percent on price competitiveness and 10 percent on fixed pricing over the contract term.